Observational registry of adalimumab use in children (4-17 years) with Juvenile Idiopathic Arthritis

Description:
Juvenile Idiopathic Arthritis (JIA) is the term used to describe a chronic arthritis in children. It involves inflammation of one or more joints usually occurring before the age of 16. JIA is an autoimmune disease meaning that the body’s own immune system begins to attack cells and tissues for an unknown reason. Treatment options vary and may include physical therapy and medications. Humira® (Adalimumab) is one of the treatment options but not much information is known about the use of the drug in pediatric patients. This study is looking to follow the long term safety and effectiveness of the medication in pediatric patients

Medication Under Study:
Humira® (Adalimumab)

Full study title:
A Long − term, Multi − center, Longitudinal Post − marketing, Observational Registry of Humira® (Adalimumab) in Children with Active Juvenile Idiopathic Arthritis (JIA)

IRB Study ID:
090503


Who may qualify:

Patients 4-17 years old with JIA

Who does not qualify:

Patients who are currently taking certain medications or unable to take Humira®

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

For urgent patient care matters involving a current study patient, please call: 330-920-5774


Lead Principal Investigator:

Photo
Mary Bratovich Toth, MD
Director, Pediatric Rheumatology
Medical Staff, President


Bookmark and Share

iGrow iGrow
Sign up for our parent enewsletter
    Contact Us

    330-543-5012

    E-mail

    find a location
    Find a location Type the first 3-5 letters of a specialty, service or location:
    Or, view: a map, a list of all locations, locations by city or locations near me.
    find a doctor
    Find a doctor Type the first 3-5 letters of the name, location or specialty:
    Or, view a list of all doctors by name, location and specialty.